Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Recurrent Head and Neck Squamous Cell Carcinoma
Clinical trial register · Taiwan

Recurrent Head and Neck Squamous Cell Carcinoma Trials in Taiwan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Taiwan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2865 matching records held by the registry are in this view. Synced 19 Nov 2026, 03:18 UTC
2865
Studies in scope
all four open statuses
1570
Recruiting now
open to new participants
340
Lead sponsors
across recruiting studies
Top sites
Kaohsiung City 3 Taichung 3 Taipei 3 Changhua 2 Tainan 2
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Recurrent Head and Neck Squamous Cell Carcinoma trials in Taiwan

4 of 2865 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Taiwan
Start
Recruiting
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
NCT06788990Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics
Phase 2/3
650
Changhua, Kaohsiung City, Taichung, Taipei
2025-01-28
Recruiting
Establishment of a Microfluidic Based Liquid Biopsy Platform for Recurrent/Metastatic Head and Neck Cancers Prognostication Using NK Cell IFN-γ Expression and CTM Correlation With DS-SACA Chip
NCT06678724Head and Neck Cancers- Squamous Cell, Head and Neck Cancer Metastatic, Recurrent Head and Neck Squamous Cell Carcinoma
National Taiwan University Hospital
Observational
30
Zhubei
2025-01-01
Recruiting
Rakuten Medical, Inc.
Phase 3
412
Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan City
2024-12-24
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 3
410
Changhua, Kaohsiung City, Taichung, Tainan, Taipei, Taoyuan
2024-01-11
Rows per page Showing 1–4 of 4
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Taiwanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-taiwan/condition/recurrent-head-and-neck-squamous-cell-carcinoma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Taiwan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,865 studies in total at the last sync on 19 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 4 of those studies listing the condition Recurrent Head and Neck Squamous Cell Carcinoma.

How many Recurrent Head and Neck Squamous Cell Carcinoma trials are recruiting in Taiwan?

4 of the 4 studies on this page are recruiting new participants as of the 19 Nov 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Recurrent Head and Neck Squamous Cell Carcinoma), 4 studies
PhaseStudiesRecruitingShare
Phase 32250%
Observational1125%
Phase 2/31125%

Most active sponsors

Lead sponsors with the most studies (Recurrent Head and Neck Squamous Cell Carcinoma)
Lead sponsorStudiesRecruiting
AVEO Pharmaceuticals, Inc.11
Bicara Therapeutics11
National Taiwan University Hospital11
Rakuten Medical, Inc.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.